期刊文献+

TGF-beta1诱导人肺腺癌PC9细胞上皮-间质转化的研究 被引量:5

Research of TGF-beta1 Inducing Lung Adencarcinoma PC9 Cells to Mesenchymal Cells Transition
下载PDF
导出
摘要 背景与目的研究表明上皮-间质转化(epithelial-mesenchymal transition,EMT)不仅参与胚胎形成与发育,而且参与肿瘤侵袭转移。此外,人转化生长因子-β1(transforming growth factor-beta1,TGF-β1)已被证实为肿瘤EMT的主要诱导剂。本研究旨在探讨TGF-β1诱导人肺腺癌PC9细胞发生EMT及其对PI3K/AKT信号通道的影响。方法将体外培养的PC9细胞用不同浓度TGF-β1处理48h,相差倒置显微镜下观察细胞形态学变化;Western blot和细胞免疫荧光验证EMT相关标记蛋白表达变化。同时,采用Western blot方法检测AKT和P-AKT的表达水平。结果TGF-β1可诱导PC9细胞向间质型细胞形态转化,并上调间质标记蛋白Fibronectin的表达及下调P-AKT的表达。结论TGF-β1可诱导PC9细胞发生EMT,并影响PI3K/AKT信号通道。 Background and objective It has been proven that epithelial-mesenchymal transition (EMT) not only correlated with embryonic development but also could promote tumor invasion and metastasis. Transforming growth factor beta-1 (TGF-β1) has been identified as the main inducer of tumor EMT. The aim of this study was to investigate the effects of TGF-β1 on EMT and PI3K/AKT signaling pathway in lung adencarcinoma PC9 cells. Methods Cultured PC9 cells were treated with different concentrations of TGF-β1 for 48 h. The morphological changes were observed under phase-contrast microscopy; EMT relative marker protein changes were assessed by Western blot and immunoflurescence staining. In addition, the expression of AKT and P-AKT were also measured by Western blot. Results The data showed that TGF-β1 could induce PC9 morphological alteration from epithelial to mesenchymal and upregulate the expression of mesenchymal maker protein Fibronectin. Obviously, the expression of P-AKT was downregulated by TGF-β1 treatment for 48 h. Conclusion TGF-β1 might induce EMT of PC9 cells, accompanied by the changes of PI3K/AKT signaling pathway.
机构地区 上海市肺科医院
出处 《中国肺癌杂志》 CAS 2010年第1期34-37,共4页 Chinese Journal of Lung Cancer
基金 国家自然科学基金资助项目(No.30872553和No.30800631) 上海市自然科学基金资助项目(No.08ZR1420900)资助~~
关键词 TGF-Β1 肺腺癌PC9细胞 EMT TGF-β1 Lung adencarcinoma PC9 cells EMT
  • 相关文献

参考文献3

二级参考文献292

  • 1Behrens J, Lowrick O, Klein-Hitpass L, Birchmeier W. The Ecadherin promoter: functional analysis of a G.C-rich region and an epithelial cell-specific palindromic regulatory element. Proc Natl Acad Sci USA 1991, 88:11495-11499
  • 2Birchmeier W, Behrens J, Weidner KM, Frixen UH, Schipper J. Dominant and recessive genes involved in tumor cell invasion. Curr Opin Cell Biol 1991, 3:832-840
  • 3Giroldi LA, Bringuier PP, de Weijert M, Jansen C, van Bokhoven A, Schalken JA. Role of E boxes in the repression of E-cadherin expression. Biochem Biophys Res Commun 1997, 241:453-458
  • 4Hajra KM, Ji X, Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 1999, 18:7274-7279
  • 5Ji X, Woodard AS, Rimm DL, Fearon ER. Transcriptional defects underlie loss of E-cadherin expression in breast cancer. Cell Growth Differ 1997, 8:773-778
  • 6Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther 2004, 3: 1058-1059
  • 7Thiery JE Morgan M. Breast cancer progression with a Twist. Nat Med 2004, 10:777-778
  • 8Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572
  • 9Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448-456
  • 10MacDonald IC, Groom AC, Chambers AF. Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays 2002, 24:885-893

共引文献282

同被引文献50

  • 1徐凌,蔡柏蔷,朱元珏,郭子建,张弘,谷丽,徐兴祥.N-乙酰半胱氨酸对大鼠慢性阻塞性肺疾病模型细胞因子和基质金属蛋白酶的影响[J].中华内科杂志,2004,43(8):595-599. 被引量:17
  • 2陈元仲,吴勇,陈萍,黄慧芳.白血病细胞TGF-β_1含量减少及外源性TGF-β_1基因对HL-60细胞的作用[J].中国病理生理杂志,2006,22(1):172-176. 被引量:19
  • 3王先升,陈建,周涛,高彦.TGF-β_1在胃癌中的表达及意义[J].山东医药,2006,46(16):49-50. 被引量:4
  • 4刘津,蔡建辉,阎庆辉,王凤安,宋伟庆,周保军,池口正英.早期胃癌组织中上皮钙粘蛋白表达与淋巴结微转移及临床病理的关系[J].癌症,2007,26(5):541-546. 被引量:4
  • 5Goldstraw P, Ball D, Jett J R, et at. Non-small-cell lung cancer[J]. Lancet, 2011 , 378 (9804) : 1727 -1740.
  • 6Linardou H, Dahabreh I J, Bafaloukos D, et at. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC [J]. Nat Rev Clin Oncol, 2009, 6(6): 352 -366.
  • 7Pao W, Chmielecki J. Rational, biologically based treatment of EGFR?mutant non-small-cell lung cancer [J]. Nat Rev Cancer, 2010, 10 ( 11 ) : 760 - 774.
  • 8Thomson S, Buck E, Petti F, et at. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition [J] . Cancer Res, 2005, 65 (20) : 9455 - 9462.
  • 9Suda K, Tomizawa K, Fujii M, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib[J]. J Thorac Oncol, 2011,6 (7) : 1152 -1161.
  • 10Therasse P, Arbuck S G, Eisenhauer E A, et at. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [J]. J Natl Cancer Inst, 2000, 92(3): 205 -216.

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部